Send me real-time posts from this site at my email

Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Moderna (MRNA) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.

Moderna is a member of our Medical group, which includes 1045 different companies and currently sits at #16 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. MRNA is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for MRNA's full-year earnings has moved 18.08% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

According to our latest data, MRNA has moved about 330.15% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 2.17% on average. This means that Moderna is performing better than its sector in terms of year-to-date returns.

To break things down more, MRNA belongs to the Medical - Biomedical and Genetics industry, a group that includes 475 individual companies and currently sits at #193 in the Zacks Industry Rank. On average, this group has gained an average of 1.26% so far this year, meaning that MRNA is performing better in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track MRNA. The stock will be looking to continue its solid performance.

Tech IPOs With Massive Profit Potential: Last years top IPOs surged as much as 299% within the first two months. With record amounts of cash flooding into IPOs and a record-setting stock market, this year could be even more lucrative. 

See Zacks’ Hottest Tech IPOs Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Moderna, Inc. (MRNA): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue